Answers are grounded in this paper and cite their sources.
Background/Objectives: We describe frontline brentuximab vedotin (BV) combined with cyclophosphamide, doxorubicin and prednisone (BV+CHP) and subsequent treatment in adults with CD30-positive peripheral T-cell lymphoma (PTCL). Methods: This single-center retrospective cohort included 18 adults treated with BV+CHP. We assessed end-of-induction response in the full cohort and recorded the first post-transplant response separately among recipients of autologous stem cell transplantation (ASCT). Overall survival (OS) and progression-free survival (PFS) were estimated from the first BV+CHP dose. Results: At the end of BV+CHP induction, before ASCT or BV maintenance where applicable, 15 of 18 patients achieved complete response (CR, 83.3%, 95% CI 58.6–96.4%). Three patients progressed during induction. Ten patients entered ASCT in first CR, and all remained in CR at the first post-ASCT assessment (median 62.5 days, range 55–70). Eight patients received BV maintenance, including five after ASCT. Three of the eight subsequently progressed and died. Median potential follow-up was 39.5 months by reverse Kaplan–Meier. The 24-month OS and PFS estimates were both 66.7% (95% CI 40.4–83.4%). Conclusions: The study describes outcomes after frontline BV+CHP in a small, histologically heterogeneous cohort. A comparative study is needed to determine whether BV maintenance affects relapse or survival.
No takes yet. Share an insight, caveat, or question.
Namdaroğlu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: